6 hours Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug LumryzZacks
The FDA approves AVDL’s Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy.
XThe FDA approves AVDL’s Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy.
X